BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38091700)

  • 1. The role of surgical management for prolactin-secreting tumors in the era of dopaminergic agonists: An international multicenter report.
    Findlay MC; Sabahi M; Azab M; Drexler R; Rotermund R; Ricklefs FL; Flitsch J; Smith TR; Kilgallon JL; Honegger J; Nasi-Kordhishti I; Gardner PA; Gersey ZC; Abdallah HM; Jane JA; Knappe UJ; Uksul N; Schroder HWS; Eördögh M; Losa M; Mortini P; Gerlach R; Antunes ACM; Couldwell WT; Budohoski KP; Rennert RC; Karsy M
    Clin Neurol Neurosurg; 2024 Jan; 236():108079. PubMed ID: 38091700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Dopamine Agonist Treatment and Surgery May Be the Best Option in Challenging Prolactinoma Cases: A Single-Centre Experience.
    Demir D; Demir AN; Sulu C; Zulfaliyeva G; Cetintas SC; Ozkaya HM; Kadioglu P; Gazioglu N; Tanriover N
    World Neurosurg; 2023 Jul; 175():e1166-e1174. PubMed ID: 37120141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
    Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
    J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
    Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
    J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.
    Abou-Al-Shaar H; Mallela AN; Patel A; Shariff RK; Shin SS; Choi PA; Faraji AH; Fazeli PK; Costacou T; Wang EW; Fernandez-Miranda JC; Snyderman CH; Gardner PA; Zenonos GA
    Pituitary; 2022 Jun; 25(3):508-519. PubMed ID: 35467273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients.
    Ottenhausen M; Conrad J; Wolters LM; Ringel F
    Neurosurg Rev; 2023 May; 46(1):128. PubMed ID: 37249700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
    Hong JW; Lee MK; Kim SH; Lee EJ
    Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transsphenoidal microsurgical results of female patients with prolactinomas.
    Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades 0-2 nonfunctioning pituitary macroadenomas at a single institution.
    Dallapiazza R; Bond AE; Grober Y; Louis RG; Payne SC; Oldfield EH; Jane JA
    J Neurosurg; 2014 Sep; 121(3):511-7. PubMed ID: 24995783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
    Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
    Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
    Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long?
    Guitelman M
    Front Horm Res; 2006; 35():88-101. PubMed ID: 16809925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.